This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential...
The HIV-focused biopharma has received its latest bid from CDMO Future Pak for a...
Human medicines European public assessment report (EPAR): Eliquis, apixaban, Dat...
Verve Therapeutics said Monday that initial data show that its investigational g...
Capping more than two years of stock-gyrating drama, Pfizer said Monday that it ...
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One yea...
Verve Therapeutics said Monday that initial data show that its investigational g...
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One yea...
Capping more than two years of stock-gyrating drama, Pfizer said Monday that it ...
The White House has ordered the National Institutes of Health to study regret an...
Recommendations of the Executive Steering Group on Shortages and Safety of Medic...
EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Gr...
Discover how QIAGEN PGXI transforms pharmacogenomics with faster, more accurate ...
With AI, the rich details hidden in unstructured clinical data are now available...
The rare disease drug landscape is evolving, with regulatory guidance shaping it...
Human medicines European public assessment report (EPAR): Trumenba, meningococca...
Human medicines European public assessment report (EPAR): Sugammadex Piramal, su...
The U.S. capacity to battle hepatitis B and C has been leveled a devastating blo...
The recent wave of layoffs and financial troubles at CRISPR-focused startups sho...
The Office on Smoking and Health at the CDC is no more, putting state quitlines ...
There are many good reasons why the U.S. should pay more for earlier access to n...
A program to upgrade technology used by community health centers across the coun...